Nutraceutical: moderate dyslipidemia and osteoarticular disease. An useful integrated treatment?

Nutraceutical: moderate dyslipidemia and osteoarticular disease. An useful integrated treatment?

Authors

  • Carmen Laurino Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con Interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, 41124, Università degli Studi di Modena e Reggio Emilia, Italia.
  • B. Palmeri Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con Interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, 41124, Università degli Studi di Modena e Reggio Emilia, Italia.
  • G. Fistetto Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con Interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, 41124, Università degli Studi di Modena e Reggio Emilia, Italia. Poliambulatorio del Secondo Parere, 41121, Modena, Italia.
  • A. Esposito Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con Interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, 41124, Università degli Studi di Modena e Reggio Emilia, Italia. Poliambulatorio del Secondo Parere, 41121, Modena, Italia.

Keywords:

Monacoline, Monascus purpureus, Astaxanthin, Omega-3, Vitamin D, total cholesterol, LDL, HDL, triglycerides, dyslipidemia

Abstract

Purpose: We evaluated the efficacy of an Omega 3 fatty acids, Monascus purpureus, quercetin, astaxanthin and vitamin D3 supplement on blood levels of total cholesterol, HDL, LDL and triglycerides (TG) on a sample of subjects affected with moderate modifications of lipid metabolism. Model: 40 subjects (21 men and 19 women) with moderate dyslipidemia [total cholesterol (202-274 mg/dL), HDL cholesterol (37-53 mg/dL), triglycerides (150-234 mg/dL), LDL cholesterol (132-172 mg/dL) and concomitant symptomatic diseases, mostly in muscle-skeletal diseases, were enrolled at the clinic of the second opinion.They were treated orally with a capsule supplement made with hypolipidemic natural products for 20 days. The measurement of the blood lipid profile was performed at the beginning and at the end of treatment. Results: total cholesterol was decreased by 13,2%, LDL cholesterol by 10,4%, and tryglicerides by 13,9%, while the values of HDL cholesterol increased by 16,3%. Conclusions: the compound has been shown to be effective for the treatment of moderate dyslipidemias.

Downloads

Published

13-01-2014

Issue

Vol. 15 (2013): Quaderno 2

Section

Original articles

License

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

 

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

1.
Laurino C, Palmeri B, Fistetto G, Esposito A. Nutraceutical: moderate dyslipidemia and osteoarticular disease. An useful integrated treatment?. Progr Nutr [Internet]. 2014 Jan. 13 [cited 2025 Feb. 23];15:3-19. Available from: https://mattioli1885journals.com/index.php/progressinnutrition/article/view/3369